Diagnosis of biotinidase deficiency is rare and usually made in infancy, through newborn screening or after presenting symptoms. We present the case of 19-year old male with progressive optic atrophy and in a second phase spinal cord syndrome unresponsive to immunosuppressive therapies. After diagnosis of profound biotinidase deficiency, oral biotin substitution was started with partial visual improvement and normalization of gait. This case highlights the possibility of late-onset biotinidase deficiency and its treatable character.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2019.04.025 | DOI Listing |
Genet Med
December 2024
Division of Genetics, Birth Defects and Metabolism, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA; Emeritus, Departments of Medical Genetics and Pediatrics, Henry Ford Hospital, Detroit, MI, USA.
BMC Glob Public Health
February 2024
Mother and Infant Research Activities (MIRA), Kathmandu, Nepal.
Background: Strategic action plans around newborn health evaluation are needed, to address the high neonatal mortality rate in Nepal. Surveillance systems, like Newborn Metabolic Screening (NBS), could reveal unrecognized drivers of neonatal death. NBS is not routinely performed in Nepal.
View Article and Find Full Text PDFBMJ Case Rep
December 2024
Department of Pediatrics, Graphic Era Institute of Medical Sciences, Dehradun, Uttarakhand, India
Biotinidase deficiency, a rare metabolic disorder characterised by abnormal biotin metabolism, affects the biotin-dependent carboxylase functions. Primarily characterised by neurological and skin disorder, it may present with myriad features. Early recognition is important for preventing long-term morbidities.
View Article and Find Full Text PDFFront Genet
November 2024
Department of Endocrinology, Genetics and Metabolism, Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi, China.
Introduction: Holocarboxylase synthetase deficiency (HLCSD) is a rare autosomal recessive genetic disorder caused by mutations in the holocarboxylase synthetase (HLCS) gene, which affects multiple systems. Common clinical manifestations include metabolic acidosis, rash, feeding difficulties, and growth retardation, with predominant involvement of the nervous system, skin, and hair. However, respiratory symptoms as the initial manifestation are relatively rare.
View Article and Find Full Text PDFTurk J Pediatr
November 2024
Division of Child Nutrition and Metabolism, Department of Pediatrics, Van Research and Training Hospital, Van, Türkiye.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!